Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version
December 9, 2020

Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version

By Matsuoka
Background: The rise within the variety of most cancers circumstances and the evolution of most cancers care administration have turn out to be a big downside for the French well being care system, thereby making affected person empowerment as a protracted sought-after purpose in continual pathologies. The implementation of an activation measure through the Affected person Activation Measure-13 merchandise (PAM-13) in the midst of most cancers care can probably spotlight the affected person’s wants, with nursing care adapting accordingly.
Goal: The goals of this PARACT (PARAmedical Interventions on Affected person ACTivation) multicentric research have been as follows: (1) consider the implementation of PAM-13 in oncology nursing practices in 5 complete most cancers facilities, (2) determine the obstacles and facilitators to the implementation of PAM-13, and (3) produce suggestions for the dissemination of such interventions in different complete most cancers facilities.
Strategies: This research will comply with the “Attain, Effectiveness, Adoption, Implementation, and Upkeep” framework and can consist of three phases. First, a strong preimplementation evaluation will probably be performed utilizing the Theoretical Domains Framework (TDF) linked to the “Functionality, Alternative, Motivation, and Conduct” mannequin to determine the obstacles and facilitators to implementing new nursing practices in every context. Then, utilizing the Conduct Change Wheel, we are going to personalize a technique for implementing the PAM-13, relying on the specificities of every context, to encourage acceptability by the nursing employees concerned within the mission. This evaluation will probably be carried out through a qualitative research by way of semistructured interviews.
Second, the affected person will probably be included within the research for 12 months, throughout which the affected person care pathway will probably be studied, significantly to gather all related contacts of oncology nurses and different well being professionals concerned within the pathway. The axes of nursing care may even be collected. The first purpose is to implement PAM-13. Secondary elements to be measured are the affected person’s nervousness stage, high quality of life, and well being literacy stage. The oncology nurses will probably be liable for finishing the questionnaires when the affected person is on the hospital for his/her intravenous chemotherapy/immunotherapy remedy. The questionnaires will probably be accomplished thrice in a 12 months: (1) on the time of the affected person’s enrollment, (2) at 6 months, and (3) at 12 months. Third, a postimplementation evaluation will probably be carried out by way of semistructured interviews utilizing the TDF to research the implementation issues at every website.
Outcomes: This research was supported by a grant from the French Ministry of Well being (PHRIP PARACT 2016-0405) and the Lucien Neuwirth Institute of Cancerology of Saint-Etienne, France. Knowledge assortment for this research is ongoing.
Conclusions: This research would enhance the carried out focused nursing interventions in most cancers facilities so {that a} affected person is obtainable a customized most cancers care pathway. Moreover, measuring the extent of activation and the implementation of measures meant to extend such activation may represent a big benefit in decreasing social well being inequalities.

Navigating uncharted waters: Creating a standardized method for evaluating and implementing biosimilar merchandise at a complete most cancers middle

Goal: The processes for formulary implementation and digital well being file (EHR) integration of biosimilar merchandise at a complete most cancers middle are described. Implications for analysis protocols are additionally mentioned.
Abstract: The present literature focuses on sensible concerns for formulary addition of biosimilar merchandise, however there’s a lack of steering on how you can implement the change, significantly throughout the EHR. Earlier than constructing the ordering instruments for biosimilars, the scientific and informatics groups ought to decide the function of biosimilars on the establishment, determine drug-specific product traits that have an effect on treatment construct, and characterize implications of future formulary adjustments or drug shortages. Leveraging an orderable file supplies the power to incorporate logic that maps to a number of merchandise and in addition permits for future implementation of adjustments throughout the treatment file fairly than requiring “swaps” on the remedy protocol stage. The institutional overview board ought to coordinate adjustments in affected analysis protocols and consent kinds and work with principal investigators to amend protocols when obligatory. Pharmacy leaders ought to develop processes to supervise stock in the course of the transition interval and decrease the chance of errors.
Conclusion: The event of a standardized method for evaluating and implementing biosimilar merchandise improves effectivity and collaboration among the many numerous group members liable for the merchandise’ integration into present workflows, together with implications for scientific analysis. Implementing biosimilars for brokers used to deal with most cancers will pose new challenges and require extra concerns. Partial implementation of biosimilars continues to pose a number of challenges within the provision of affected person care.
Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version

Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version

Matrix stiffness epigenetically regulates the oncogenic activation of the Sure-associated protein in gastric most cancers

In lots of cancers, tumour development is related to elevated tissue stiffness. But, the mechanisms associating tissue stiffness with tumorigenesis and malignant transformation are unclear. Right here we present that in gastric most cancers cells, the stiffness of the extracellular matrix reversibly regulates the DNA methylation of the promoter area of the mechanosensitive Sure-associated protein (YAP). Reciprocal interactions between YAP and the DNA methylation inhibitors GRHL2, TET2 and KMT2A may cause hypomethylation of the YAP promoter and stiffness-induced oncogenic activation of YAP.

Human Cancer Antigen 15-3 (CA 15-3) ELISA Kit

PRB-5069 96 assays
EUR 686.4

Human Cancer Antigen 15-3 (CA 15-3) ELISA Kit

PRB-5069-5 5 x 96 assays
EUR 2739.6

Cancer Antigen 15-3 MUC 1 Antigen (Human Milk)

VAng-Cr3871-10kU 10 kU
EUR 505.2
Description: Cancer Antigen 15-3 MUC 1 Antigen, Host/Source: Human Milk. The purity is detected by salt extraction and delipidization following high speed centrifugation. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2.

Paraffin Tissue Section - Human Breast Tumor: Lobular carcinoma

T2235086-3 5 slides
EUR 308.4
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Breast Cancer-Associated Antigen BRCAA1 (BRCAA1) Antibody

20-abx148333
  • EUR 510.00
  • EUR 410.40
  • 100 ug
  • 50 ug

BSA (Standard Grade)

30-AB70 1 kg
EUR 1078.8
Description: Standard Grade Bovine Serum Albumin (99% pure)

Cancer Antigen 15-3 MUC 1 Antigen (Human Ascites Fluid)

VAng-Cr3872-10kU 10 kU
EUR 1363.2
Description: Cancer Antigen 15-3 MUC 1 Antigen, Host/Source: Human Ascites Fluid.

Cancer Antigen CA 15-3 Protein (Human Fluids)

VAng-Wyb8628-inquire inquire Ask for price
Description: CA 15-3 (Breast Cancer Antigen), Cancer antigen from Human Fluids, 12.240 kU/mL.

Cancer Antigen CA 15-3 Protein (Human Milk)

VAng-Wyb8631-inquire inquire Ask for price
Description: CA 15-3 (Breast Cancer Antigen), Antigen Grade, Cancer antigen from Human Milk, 33.0 kIU/mL.

Breast Cancer Exosome

P141-BR - Ask for price

Organic Wine Standard 3

WINE-3 1ML
EUR 258.78

Paraffin Tissue Section - Human Brain Tumor: Astrocytoma Grade III

T2235035-3 5 slides
EUR 308.4
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Cancer Antigen 15-3 (CA15-3) (human) ELISA Kit

K4804-100 100 assays
EUR 1000.8
Description: Sensitive, Colorimetric Assay

Human Cancer PrimaCell4: Breast Tumor Cells Growth Medium

9-46027 5 x 100 ml Ask for price

Human Cancer Tissue Preparation Buffer 4: Breast Tumor Cells

9-80027 1 x 100 ml Ask for price

Breast Cancer Exosome RNA

P241-BR - Ask for price

Fluorescent Exosome Standard (Urine )

ESF-15 100 µg
EUR 2067.6
Description: Fluorescent exosomes are labeled with green dye, which offer a stable fluorescent labeling.

Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit

DLR-CA15-3-Hu-48T 48T
EUR 574.8
Description: A sandwich quantitative ELISA assay kit for detection of Human Carbohydrate Antigen 15-3 (CA15-3) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit

DLR-CA15-3-Hu-96T 96T
EUR 745.2
Description: A sandwich quantitative ELISA assay kit for detection of Human Carbohydrate Antigen 15-3 (CA15-3) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit

RDR-CA15-3-Hu-48Tests 48 Tests
EUR 600

Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit

RDR-CA15-3-Hu-96Tests 96 Tests
EUR 830.4

Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit

RD-CA15-3-Hu-48Tests 48 Tests
EUR 573.6

Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit

RD-CA15-3-Hu-96Tests 96 Tests
EUR 794.4

99445-15 DCT 15 X 85MM

99445-15 250/pk
EUR 116.4
Description: Disposable Culture Tubes; DCT's, CGW

ICP-MS Calibration Standard 3

CL-CAL-3 125ML
EUR 121.98

Proteinase K, Recombinant, Standard Grade

9250-100
EUR 124.8

Proteinase K, Recombinant, Standard Grade

9250-10G
EUR 4627.2

Proteinase K, Recombinant, Standard Grade

9250-1G
EUR 548.4

Proteinase K, Recombinant, Standard Grade

9250-500
EUR 314.4

Proteinase K, Recombinant, Standard Grade

9251-100
EUR 1266

Proteinase K, Recombinant, Standard Grade

9251-25
EUR 352.8

Proteinase K, Recombinant, Standard Grade

9251-5
EUR 144

Cancer Antigen 242 Antigen

VAng-Cr3876-10kU 10 kU
EUR 505.2
Description: Cancer Antigen 242 Antigen, Host/Source: Metastatic Liver. The purity is detected by gel filtration.

Cancer Antigen 50 Antigen

VAng-Cr3877-50kU 50 kU
EUR 6642
Description: Cancer Antigen 50 Antigen, Host/Source: Human Cell Culture. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2.

CA 15-3, Human Breast Adenocarcinoma

P1435-1
EUR 130.8

CA 15-3, Human Breast Adenocarcinoma

P1435-5
EUR 288

Polystyrene Particle Size Standard

PPS-3 mL
EUR 152.4
Description: Please reffer to the technical data sheet for more detail information for this item. Our dedicated team would be happy to assist you via live chat, email or phone.

Inactivated CMV Grade 3 Antigen

VAng-Lsx0038-1mg 1 mg
EUR 2503.2
Description: CMV Grade 3, natural protein.

Inactivated MuV Grade 3 Antigen

VAng-Lsx0411-inquire inquire Ask for price
Description: MuV grade 3, native protein.

Inactivated Rotavirus Grade 3 Antigen

VAng-Lsx0469-inquire inquire Ask for price
Description: Rotavirus Grade 3, native virus.

Inactivated RuV Grade 3 Antigen

VAng-Lsx0476-1mL 1 mL
EUR 474
Description: RuV Grade 3, natural protein.

Breast Cancer Metastasis Suppressor 1

PR27265 2 ug
EUR 229.2

ICP-MS Instrument Check Standard 3

CL-ICS-3 125ML
EUR 175.56

Breast Tumor Kinase antibody

70R-31875 100 ug
EUR 392.4
Description: Rabbit polyclonal Breast Tumor Kinase antibody

Breast Tumor Kinase antibody

70R-33385 100 ug
EUR 392.4
Description: Rabbit polyclonal Breast Tumor Kinase antibody

Breast Tissue Lysate (Tumor)

1713-01 0.1 mg
EUR 336.3
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)

1713-02 0.1 mg
EUR 336.3
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)

1714-01 0.1 mg
EUR 336.3
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)

1714-02 0.1 mg
EUR 336.3
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)

1714-03 0.1 mg
EUR 336.3
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)

1714-04 0.1 mg
EUR 336.3
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)

1714-05 0.1 mg
EUR 336.3
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)

1714-06 0.1 mg
EUR 336.3
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)

1714-07 0.1 mg
EUR 336.3
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Human Breast Tumor lysate

HTL-1323 1 mg
EUR 927.6

Breast Membrane Tumor Lysate

XBL-10499 0.1 mg
EUR 752.1
Description: Human breast tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human breast tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated breast tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated breast tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal.

Cancer Antigen 72-4 Antigen

VAng-Cr3878-10kU 10 kU
EUR 505.2
Description: Cancer Antigen 72-4 Antigen, Host/Source: Metastatic Liver. The purity is ~65% by SDS-PAGE. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2.

Microplate cell grade 96well ps standard

781965 PK50
EUR 347.47

Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody

20-abx171475
  • EUR 1028.40
  • EUR 526.80
  • 1 mg
  • 200 ug

Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody

20-abx133658
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody

20-abx129227
  • EUR 510.00
  • EUR 159.60
  • EUR 1446.00
  • EUR 693.60
  • EUR 393.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody

20-abx013807
  • EUR 376.80
  • EUR 117.60
  • EUR 477.60
  • EUR 594.00
  • 100 ug
  • 10 ug
  • 200 ug
  • 300 µg

Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody

abx025588-400ul 400 ul
EUR 627.6

Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody

abx025588-80l 80 µl
EUR 343.2

Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody

20-abx324781
  • EUR 376.80
  • EUR 292.80
  • 100 ug
  • 50 ug

Recombinant Breast Cancer Anti-Estrogen Resistance 3 (BCAR3)

4-RPG768Hu01
  • EUR 601.69
  • EUR 284.40
  • EUR 1926.34
  • EUR 722.11
  • EUR 1324.22
  • EUR 477.60
  • EUR 4635.84
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Human Breast Cancer Anti-Estrogen Resistance 3 expressed in: E.coli

Human CA15-3 Antigen Grade Protein

abx060972-250kU 250 kU
EUR 2380.8

Inactivated PIV-3 Grade 2 Antigen

VAng-Wyb3637-1mL 1 mL
EUR 1363.2
Description: Parainfluenza virus type 3 (strain C243) Grade 2, natural antigen

Inactivated HSV-1 Grade 3 Antigen

VAng-Lsx0293-1mg 1 mg
EUR 1786.8
Description: HSV Type 1 Grade III, native antigen.

Inactivated HSV-2 Grade 3 Antigen

VAng-Lsx0302-1mg 1 mg
EUR 1786.8
Description: HSV Type 2 Grade III, native antigen.

Breast Cancer Metastasis Suppressor 1 Protein

20-abx263402
  • EUR 1930.80
  • EUR 393.60
  • EUR 276.00
  • 100 ug
  • 10 ug
  • 2 µg

Autobioluminescent Human Breast Cancer Cells (MCF7)

ASE-5903 1 ml
EUR 2490
Description: 6 month

Autobioluminescent Human Breast Cancer Cells (T47D)

ASE-5904 1 ml
EUR 2490
Description: 6 month

Human Breast Cancer Signaling Primer Library

HBRCA-I 1 set
EUR 657.6

Breast Cancer Anti-Estrogen Resistance 1

PR27245 2 ug
EUR 229.2

Anti-Breast Cancer Resistance Protein antibody

STJ16100903 1 mL
EUR 573.6

Anti-Breast Cancer Resistance Protein antibody

STJ16100916 1 mL
EUR 573.6

anti-Breast cancer suppressor candidate 1

YF-PA24096 50 ul
EUR 400.8
Description: Mouse polyclonal to Breast cancer suppressor candidate 1

anti-Breast cancer suppressor candidate 1

YF-PA12974 50 ul
EUR 435.6
Description: Mouse polyclonal to Breast cancer suppressor candidate 1

anti-Breast cancer suppressor candidate 1

YF-PA12975 50 ug
EUR 435.6
Description: Mouse polyclonal to Breast cancer suppressor candidate 1

Prostate Specific Antigen Std Grade Antigen

VAng-Cr3891-1mg 1 mg
EUR 604.8
Description: Prostate Specific Antigen Std Grade Antigen, Host/Source: Human Seminal Fluid. The purity is detected by salt precipitation.

CEA Antigen Grade Protein

abx060976-05mg 0.5 mg
EUR 1161.6

CEA Antigen Grade Protein

abx060977-1mg 1 mg
EUR 2030.4

Pesticide Mix 3 Containing 15 Compounds in Acetonitrile

SPXPR-3 1ML
EUR 214.32

9998 SCREW CAP 415/15

9998-15 288/pk
EUR 237.6
Description: General Apparatus; Stoppers

Breast Tumor Tissue Array - 16 cases of breast cancer, each in duplicates, paired with adjacent normal tissues

Z7020007 5 slides
EUR 1657.2
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Human Cancer Antigen CA15-3 Protein

abx060965-50kU 50 kU
EUR 3150

Groundwater and Wastewater Pollution Control Check Standard

WP-3 125ML
EUR 112.86

Cancer Antigen 125 Antigen (Human Adenocarcinoma)

VAng-Cr3868-10kU 10 kU
EUR 505.2
Description: Cancer Antigen 125 Antigen, Host/Source: Human Adenocarcinoma. The purity is detected by salt extraction and chromatography.

Cancer Antigen 125 Antigen (Ascites Fluid)

VAng-Cr3870-10kU 10 kU
EUR 1132.8
Description: Cancer Antigen 125 Antigen, Host/Source: Ascites Fluid. The purity is ≥ 95% by SDS-PAGE.

Cancer Antigen CEA Antigen (Human Fluids)

VAng-Wyb8644-inquire inquire Ask for price
Description: Carcinoembryonic Antigen, Calibrator Grade, Cancer antigen from Human Fluids, 1.13 mg/mL.

Breast Tumor Kinase Blocking Peptide

AF4768-BP 1mg
EUR 234

Breast Tumor Kinase antibody (Tyr447)

70R-33384 100 ug
EUR 392.4
Description: Rabbit polyclonal Breast Tumor Kinase antibody (Tyr447)

Human Tumor Tissue: Breast cDNA

HT05-090 10 rxn
EUR 498

Human Cancer Antigen CA125 (Ovarian Cancer) Protein

abx061590-100kU 100 kU
EUR 1446

Vitamin A Reference Standard (USP grade powder)

51R-U716002 10 pack
EUR 619.2
Description: Vitamin A Reference Standard (USP grade powder) chemical reference substance

Anti-Rabbit Whole Serum | GWS-15

GWS-15 1.0 mL
EUR 130
Description:

Anti-Rabbit Whole Serum | GWS-15 | Immunology Consultants Laboratory

Host: Goat

Format: Whole Serum

Product Type: Primary Antibody

Antibody Clonality: Polyclonal

Liquid Wicks, Size 15, 200 /pk

W-15 200 WICKS
EUR 22
Description: Liquid Wicks, Size 15, 200 /pk

Cancer of the breast, 75 cases (1.1mm), set 3

BRC1503 1
EUR 300
Description: Breast cancer tissue array, set 3, non-overlapping with BRC1501, BRC1502, BRC1504 to BRC15011,150 cores from normal/benign (5 cases) and cancer (70 cases) tissues in duplicates with grading, TNM staging data, AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data.

Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Protein

20-abx168253
  • EUR 844.80
  • EUR 343.20
  • EUR 2598.00
  • EUR 994.80
  • EUR 594.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody

20-abx134976
  • EUR 427.20
  • EUR 644.40
  • EUR 260.40
  • 100 ul
  • 200 ul
  • 30 ul

Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody

abx010337-100ug 100 ug
EUR 526.8

Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody

abx432398-200ul 200 ul
EUR 460.8

Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody

abx218562-100ug 100 ug
EUR 526.8

Breast Cancer Estrogen Resistance 3 (BCAR3) Polyclonal Antibody (Human)

4-PAG768Hu01
  • EUR 296.40
  • EUR 3012.00
  • EUR 750.00
  • EUR 372.00
  • EUR 256.80
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
Description: A Rabbit polyclonal antibody against Human Breast Cancer Estrogen Resistance 3 (BCAR3)

Paraffin Tissue Section - Human Pancreas Tumor: Islet Cell Tumor

T2235188-3 5 slides
EUR 308.4
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Recombinant Human IL-15 Protein

PROTP40933-3 10ug
EUR 380.4
Description: IL-15 is an immunomodulating cytokine that stimulates the proliferation of T lymphocytes and shares many biological properties with IL-2. IL-15 exerts its biological activites primarily on T cells. It is also essential in the development, survival and activation of NK cells. Increased expression of IL-15 has been implicated with rheumatoid arthritis, inflammatory bowel disease and diseases affiliated with retroviruses HIV and HTLV-I. Human IL-15 is biologically active on mouse cells as measured by the dose-dependent stimulation of the proliferation of mouse CTLL cells. Recombinant human IL-15 is a 12.9 kDa protein consisting of 114 amino acid residues.

Swine IL-15 Recombinant Protein

R00212-3 5ug/vial
EUR 310.8
Description: Interleukin-15 (IL-15) is a cytokine with structural similarity to IL-2 that is secreted by mononuclear phagocytes following infection by virus(es). This cytokine induces cell proliferation of natural killer cells. Swine IL-15 Recombinant Protein is purified interleukin-15 produced in yeast.

Paraffin Tissue Section - Human Breast Tumor: Male Breast Hyperplasia

T2235086-4 5 slides
EUR 308.4
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Paraffin Tissue Section - Human Breast Tumor: Medullarycarcinoma of Breast

T2235086-5 5 slides
EUR 308.4
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Inactivated MuV Grade 3 Antigen (Strain Enders)

VAng-0619Lsx-inquire inquire Ask for price
Description: MuV (Strain Enders) grade 3, native protein. 0.45 mg/mL.

Human Breast cancer metastasis-suppressor 1 (BRMS1)

1-CSB-RP048144h
  • EUR 456.00
  • EUR 256.80
  • EUR 1570.80
  • EUR 672.00
  • EUR 1047.60
  • EUR 314.40
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human Breast cancer metastasis-suppressor 1(BRMS1),partial expressed in E.coli

Cancer of the breast, 102 cases (1.5mm)

BRC1021 1
EUR 300
Description: Breast cancer tissue array, 102 cases of normal/benign (5 cases) and cancer (97 cases) tissues, with grading, TNM staging, and AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data.

Cancer of the breast, 228 cases (1.1mm)

BRC2281 1
EUR 552
Description: Breast cancer tissue array containing 8 cases of normal/benign conditions and 220 cases of cancers with grading, TNM staging, and AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data.

Cancer of the breast, 49 cases (2mm)

BRC491 1
EUR 228
Description: Breast cancer tissue array, non-overlapping with BRC711, 49 cases of normal/benign and cancer tissues with grading, TNM staging, and AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data.

Cancer of the breast, 71 cases (1.1mm)

BRC711 1
EUR 228
Description: Breast cancer tissue array, non-overlapping with BRC491, 71 cases of normal/benign and cancer tissues with grading, TNM staging data, AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data.

Breast cancer-overexpressed gene 1 protein Antibody

48092-100ul 100ul
EUR 399.6

Breast cancer-overexpressed gene 1 protein Antibody

48092-50ul 50ul
EUR 286.8

Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody

20-abx104049
  • EUR 493.20
  • EUR 159.60
  • EUR 1378.80
  • EUR 678.00
  • EUR 376.80
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody

20-abx104050
  • EUR 526.80
  • EUR 159.60
  • EUR 1496.40
  • EUR 710.40
  • EUR 393.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody

20-abx104051
  • EUR 493.20
  • EUR 159.60
  • EUR 1378.80
  • EUR 678.00
  • EUR 376.80
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody

20-abx171476
  • EUR 978.00
  • EUR 510.00
  • 1 mg
  • 200 ug

Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody

20-abx171477
  • EUR 978.00
  • EUR 510.00
  • 1 mg
  • 200 ug

Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody

20-abx175628
  • EUR 1412.40
  • EUR 693.60
  • 1 mg
  • 200 ug

Breast Cancer Cell Protein 2 (BRCC2) Antibody

20-abx141388
  • EUR 444.00
  • EUR 727.20
  • EUR 360.00
  • 100 ul
  • 200 ul
  • 50 ul

Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody

20-abx130340
  • EUR 526.80
  • EUR 159.60
  • EUR 1479.60
  • EUR 710.40
  • EUR 393.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody

20-abx129675
  • EUR 510.00
  • EUR 159.60
  • EUR 1412.40
  • EUR 693.60
  • EUR 393.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody

20-abx129746
  • EUR 360.00
  • EUR 159.60
  • EUR 961.20
  • EUR 510.00
  • EUR 309.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Breast Cancer Metastasis-Suppressor 1 (BRMS1) Antibody

20-abx008216
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Breast Cancer Metastasis-Suppressor 1 (BRMS1) Antibody

20-abx008217
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Breast Cancer Metastasis-Suppressor 1 (BRMS1) Antibody

abx030985-400ul 400 ul
EUR 627.6

Breast Cancer Metastasis-Suppressor 1 (BRMS1) Antibody

abx030985-80l 80 µl
EUR 343.2

Breast Cancer Metastasis-Suppressor 1 (BRMS1) Antibody

abx230960-100ug 100 ug
EUR 577.2

Breast Cancer Anti-Estrogen Resistance 1 Protein

20-abx262743
  • EUR 393.60
  • EUR 7676.40
  • EUR 276.00
  • 10 ug
  • 1 mg
  • 2 µg

Breast Cancer Metastasis-Suppressor 1 (BRMS1) Antibody

20-abx327442
  • EUR 376.80
  • EUR 292.80
  • 100 ug
  • 50 ug

Breast Cancer Metastasis-Suppressor 1 (BRMS1) Antibody

20-abx328607
  • EUR 376.80
  • EUR 292.80
  • 100 ug
  • 50 ug

Breast Cancer Metastasis-Suppressor 1 (BRMS1) Antibody

20-abx241361
  • EUR 493.20
  • EUR 360.00
  • 100 ul
  • 50 ul

Breast Cancer Metastasis-Suppressor 1 (BRMS1) Antibody

20-abx241362
  • EUR 493.20
  • EUR 360.00
  • 100 ul
  • 50 ul

SNCG (breast cancer-specific protein 1) Antibody

BF0110 200ul
EUR 540

Anti-Human Breast Cancer Resistance Protein antibody

STJ16100907 1 mL
EUR 573.6

Anti-Mouse Breast Cancer Resistance Protein antibody

STJ16100917 1 mL
EUR 573.6

Recombinant Breast Cancer Susceptibility Protein 2 (BRCA2)

4-RPB364Hu01
  • EUR 636.10
  • EUR 294.00
  • EUR 2055.36
  • EUR 765.12
  • EUR 1410.24
  • EUR 501.60
  • EUR 4958.40
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Human Breast Cancer Susceptibility Protein 2 expressed in: E.coli
Direct alteration of extracellular cues through in situ matrix softening reversed YAP exercise and the epigenetic program. Our findings recommend that epigenetic reprogramming of the mechanophysical properties of the extracellular microenvironment of stable tumours might symbolize a therapeutic technique for the inhibition of most cancers development.